EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation

Lili Su iD, Xiangyu Zhang, Mengrong Li iD, Ying Li, Dong Wang

Expert Review of Pharmacoeconomics & Outcomes Research · 2025

DOI: 10.1080/14737167.2025.2518135 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Lili Su und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin, China. Hauptthemen laut MEDLINE: Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Quinazolinones, Acrylamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Wu Jieping Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the cost-effectiveness of osimertinib compared to dacomitinib for advanced non-small cell lung cancer with EGFR mutation from the perspective of China's health system. METHODS: Based on the FLAURA clinical trial and network meta-analysis, a partitioned survival model was constructed with a model simulation timeframe of 10 years and a 3-week cycle. Cost and quality-adjusted life years (QALYs) were used as model output indicators, and the incremental cost-effectiveness ratio was calculated to determine the economic feasibility of osimertinib compared to dacomitinib through cost-utility analysis. Sensitivity analysis was applied to test the robustness of the model. RESULTS: The basic analysis results indicate that the osimertinib group incurred an additional cost of 138,487 Chinese Yuan (CNY) compared to the dacomitinib group, but gained an additional 0.32 QALYs. The incremental cost-effectiveness ratio is 436,203 CNY, which is higher than three times China's per capita GDP. CONCLUSION: Under the threshold of three times China's per capita GDP, osimertinib appears not to be cost-effective compared to dacomitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsCarcinoma, Non-Small-Cell LungQuinazolinonesAcrylamidesLung NeoplasmsHumansCost-Benefit AnalysisMutationErbB ReceptorsQuality-Adjusted Life YearsChinaAntineoplastic AgentsNetwork Meta-Analysis as TopicSurvival AnalysisIndolesPyrimidines

Stichwörter der Autor:innen

Osimertinibcost-utility analysisdacomitinibnon-small cell lung cancerpartitioned survival model

Substanzen

osimertinibAniline CompoundsdacomitinibQuinazolinonesAcrylamidesErbB ReceptorsEGFR protein, humanAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin, China.
  • Department of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

ORCID-Profile: Lili Su, Mengrong Li

Förderung

  • Wu Jieping Medical Foundation

Zitieren

APA

Su, L., Zhang, X., Li, M., Li, Y., & Wang, D. (2025). Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2518135

Vancouver

Su L, Zhang X, Li M, Li Y, Wang D. Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2518135

BibTeX
@article{Su2025,
  author = {Su, Lili and Zhang, Xiangyu and Li, Mengrong and Li, Ying and Wang, Dong},
  title = {Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2025},
  doi = {10.1080/14737167.2025.2518135}
}
Kostenlos starten →